Sökning: WFRF:(Ingemansson Johan) >
C-reactive protein-...
-
Gyllensvärd, JohanLinköpings universitet,Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, H.K.H. Kronprinsessan Victorias barn- och ungdomssjukhus,Univ Gothenburg, Sweden
(författare)
C-reactive protein- and clinical symptoms-guided strategy in term neonates with early-onset sepsis reduced antibiotic use and hospital stay: a quality improvement initiative.
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
2020-11-20
-
Springer Science and Business Media LLC,2020
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/299616
-
https://gup.ub.gu.se/publication/299616URI
-
https://doi.org/10.1186/s12887-020-02426-wDOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-172093URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Futurum -the academy for healthcare, Region Jonkoping County; Swedish government; county council, the ALF [117661]
-
Early-onset sepsis (EOS) is a potentially life-threatening complication of birth. Clinical symptoms are often unspecific and biomarkers have low predictive values for EOS. Therefore, clinical suspicion often leads to antibiotic therapy in neonates with a negative blood culture. In the study we evaluated if a quality improvement initiative could reduce unwarranted antibiotic use in a safe way in term neonates with culture-negative sepsis.The quality improvement initiative included new treatment guidelines and were introduced on 11 June 2018. The guidelines included C-reactive protein- and clinical symptoms-guided decision-making and shorter intravenous antibiotic therapy. All term neonates treated for EOS at Ryhov Hospital, Jönköping, Sweden were studied before (period 1: 2016-2017) and after the introduction of the new guidelines (period 2: 11 June 2018 to 30 Sept 2019). Laboratory and clinical data were analysed.There were 7618 term neonates in period 1 and 5005 term neonates in period 2. We identified 140 (1.8%) EOS in period 1 and 97 (1.9%) EOS in period 2. During period 1 and 2, there were 61 (61/140, 44%) and 59 (59/97, 61%) EOS neonates, respectively, who met the criteria for shorter antibiotic treatment. The number of positive blood cultures were seven (0.92/1000 live births) and five (1.0/1000 live births) in period 1 and 2. The median C-reactive protein were 52mg/L (37-62) in period 1 and 42mg/L (31-56) in period 2 in the group who met the criteria of the guidelines. The duration of antibiotic therapy (Median: seven vs. five days, p<0.001) and hospital stay (Median: seven vs. five days, p<0.001) as well as healthcare costs (decreased by €122,000/year) was reduced in the group who met the criteria after the introduction of the guidelines.C-reactive protein- and clinical symptoms-guided decision-making for EOS significantly decreased the duration of antibiotic therapy and hospital stay, and hence reduced healthcare costs, with no reinfection in a cohort of term infants.Trial registration number: ISRCTN29535824 . Date of registration: 28 May 2020. Retrospectively registered.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Ingemansson, FredrikLinköpings universitet,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Dept Pediat, Sweden(Swepub:liu)frein59
(författare)
-
Hentz, ElisabetSahlgrens Univ Hosp, Sweden
(författare)
-
Studahl, Marie,1957Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine,Univ Gothenburg, Sweden; Reg Vastra Gotaland, Sweden(Swepub:gu)xstuma
(författare)
-
Elfvin, Anders,1971Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics,Univ Gothenburg, Sweden; Sahlgrens Univ Hosp, Sweden(Swepub:gu)xelfan
(författare)
-
Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för pediatrik
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:BMC pediatrics: Springer Science and Business Media LLC20:11471-2431
Internetlänk
Hitta via bibliotek
Till lärosätets databas